Navigation Links
Valeant Pharmaceuticals Announces Private Exchange Offer
Date:3/29/2013

MONTREAL, March 29, 2013 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) announced today that its wholly owned subsidiary Valeant Pharmaceuticals International (the "Company") intends to commence an offer to exchange (the "Exchange Offer") any and all of its outstanding $500 million aggregate principal amount of 6.375% Senior Notes due 2020 (the "Existing Notes") for up to an additional $500 million aggregate principal amount of its 6.375% Senior Notes due 2020 (the "Exchange Notes") issued pursuant to the indenture, dated as of October 4, 2012 (the "Date of Issuance"), as supplemented, among the Company, Valeant Pharmaceuticals International, Inc. (the "Parent"), the guarantors named therein and The Bank of New York Mellon Trust Company, as trustee.

The Exchange Notes will be guaranteed by same guarantors of the Existing Notes, which are the Parent and each of the Parent's subsidiaries (other than the Company) that is a guarantor of the Parent's senior secured credit facilities. The form and terms of the Exchange Notes will be substantially identical to the form and terms of the Existing Notes.  The Company is conducting this Exchange Offer in order to satisfy its obligations under the indenture governing the Existing Notes with the anticipated result being that some or all of such notes will be part of a single series of notes under one indenture using a single CUSIP number.

Upon the terms and subject to the conditions of the Exchange Offer, for each $1,000 principal amount of Existing Notes validly tendered, and not withdrawn, in the Exchange Offer for the Existing Notes, eligible holders will receive $1,000 principal amount of Exchange Notes.

The Exchange Offer will expire at 5:00 p.m., New York City time, on April 26, 2013, unless extended or earlier terminated by the Company (such date and time, as the same may be extended or earlier terminated, the "Expiration Time"). Eligible holders that validly tender their Existing Notes and do not withdraw their tenders at or prior to 5:00 p.m., New York City time, on April 9, 2013 (such date and time, the "Initial Expiration Time") will receive Exchange Notes on April 10, 2013.

Tenders in the Exchange Offer may be validly withdrawn at any time prior to the Initial Expiration Time, but will thereafter be irrevocable, except as required by applicable securities laws. 

The Company may extend or terminate the Exchange Offer, in its sole and absolute discretion, and otherwise amend or modify the Exchange Offer in any respect, subject to applicable securities laws.  The Exchange Offer is open to all eligible holders of Existing Notes. 

The Exchange Notes have not been and will not be registered under the Securities Act of 1933, as amended (the "Securities Act") or any state securities laws.  The Exchange Notes may not be offered or sold in the United States or to any U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.  The Exchange Offer is being made, and the Exchange Notes are being offered, and issued only to holders of Existing Notes who are "qualified institutional buyers" (as defined in Rule 144A under the Securities Act) or institutional "accredited investors" within the meaning of Rule 501 (a)(1), (2), (3) or (7) of Regulation D under the Securities Act.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any offer or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

About Valeant Pharmaceuticals International, Inc.
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, neurology and branded generics.  More information about Valeant Pharmaceuticals International, Inc. can be found at www.valeant.com.

Forward Looking Statements
This press release may contain forward-looking statements, including, but not limited to those related to the offering of Exchange Notes and whether or not the Company will consummate the offering.  Forward-looking statements can generally be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "should," "would," "intend," "seem," "potential," "appear," "continue," "future," believe," "estimate," "forecast," "project," variations of such words or other words that convey uncertainty of future events or outcome, although not all forward-looking statements contain these identifying words.  Our forward-looking statements are subject to known and unknown risks and uncertainties, many of which are outside of our control and could cause actual results to differ materially and adversely from those expressed or implied by such statements.  Those risks include, but are not limited to: our future economic performance, operating results, financial condition, capital resources or prospects; projections of revenue, expenses, income and losses, earnings (losses) per share, capital expenditures, dividends, growth rates or other financial items; market or industry trends, legal or regulatory developments; future events;  the anticipated effect of acquisitions, litigation, new (or changes to existing) laws, regulations or accounting principles or other matters on our business, economic performance, operating results, financial condition, capital resources or prospects; our plans, objectives and strategies for future operations or otherwise; and our expectations and beliefs.  Information concerning potential factors that could affect the Company's financial results is included in its Parent's most recent annual or quarterly report and detailed from time to time in the Parent's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators.  Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof.  The Company and Parent undertake no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes.

(Logo: http://photos.prnewswire.com/prnh/20101025/LA87217LOGO)

Contact Information:
Laurie W. Little
949-461-6002
laurie.little@valeant.com


'/>"/>
SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Valeant Pharmaceuticals Agrees To Acquire AcneFree And Certain Assets From University Medical
2. Valeant Pharmaceuticals Reports 2012 First Quarter Financial Results
3. Valeant Pharmaceuticals To Host Investor Day
4. Valeant Pharmaceuticals To Announce 2012 Second Quarter Results On August 2, 2012
5. Valeant Pharmaceuticals International, Inc. Agrees To Acquire Medicis Pharmaceutical Corporation For $44.00 Per Share In Cash
6. Valeant Pharmaceuticals To Present At UBS Annual Global Life Sciences Conference
7. Valeant Pharmaceuticals Announces Management Change
8. Valeant Pharmaceuticals To Syndicate Incremental Loans
9. Valeant Pharmaceuticals Appoints Howard Schiller To Board Of Directors
10. Valeant Pharmaceuticals Announces Launch of Concurrent Private Offerings of Senior Notes
11. Valeant Pharmaceuticals International, Inc. Announces Pricing Of Concurrent Private Offerings Of Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Research and Markets has announced the addition of the ... their offering. ... The interventional radiology products market is expected to reach USD 8.02 ... CAGR of 4.8%. This market is segmented based on type, procedure, ... of this market are rising incidence of chronic diseases, rising geriatric ...
(Date:1/23/2017)... 23, 2017  Delcath Systems, Inc. (NASDAQ: ... treatment of primary and metastatic liver cancers, today announced ... President and Chief Executive Officer of Delcath will be ... Markets, Thirteenth Annual Investor Conference at the Boca Raton ... , on Tuesday, January 31, 2017 at 10:30 ...
(Date:1/23/2017)... , January 23, 2017 ... (r enal) y el riesgo ... de a pabetalone    Resverlogix Corp. ... resultados preliminares de un ensayo en fase 1 con ... de riñón (renal) severa. Los datos demostraron unos resultados ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... ... new plugin that allows sleep centers to automatically connect and initialize all their ... thin client browser plugin is quickly installed on first use and then monitors ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... website this week at a new domain address. Alpine Springs Rehabilitation & Recovery ... has also debuted a new logo along with its redesigned and retooled website. ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... life science companies, has achieved ISO 17100:2015 certification following a comprehensive audit ... is the globally recognized standard that establishes guidance for critical processes within ...
(Date:1/23/2017)... ... January 23, 2017 , ... DMG Productions is ... Ed Begley, Jr., scheduled to broadcast Saturday, January 28, 2017 at 5:00pmEST. , ... in 2008 to address the limitations of fatigue monitoring technologies within the mining ...
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... Wooden and plastic balance boards have been ... and improve balance. Kumo Board is the first and only balance board to ... to be soft and rigid at the same time as well as skill-level adjustable for ...
Breaking Medicine News(10 mins):